Metacytofilin 是弓形虫病的有力候选治疗药物
本研究从真菌 Metarhizium 属中鉴定出 metacytofilin(MCF),在体外和体内评估其抗弓形虫活性。MCF 抑制胞内外弓形虫活力,腹腔或口服给药提高感染小鼠存活率,口服可预防妊娠小鼠垂直传播,RNAseq 显示其抑制寄生虫 DNA 复制并增强 RNA 降解。MCF 是抗弓形虫病药物开发的有力候选。
要点
- MCF 在体外抑制胞内和胞外弓形虫活力。
- 感染后腹腔或口服 MCF 提高小鼠存活率。
- 妊娠小鼠口服 MCF 可预防弓形虫垂直传播。
核心结论
- MCF 具有强抗弓形虫活性,是未来弓形虫病药物开发的有力候选。
研究设计与样本
- 从真菌 Metarhizium 属中鉴定 MCF,用非妊娠和妊娠小鼠进行体外和体内抗弓形虫活性评估。
- 通过 RNAseq 研究宿主和寄生虫基因 RNA 表达以了解 MCF 作用机制。
主要发现
- 体外 MCF 抑制胞内和胞外弓形虫活力。
- 感染弓形虫速殖子后腹腔或口服给予 MCF 较未治疗动物提高小鼠存活率。
- 妊娠小鼠口服 MCF 预防寄生虫垂直传播。
- RNAseq 显示 MCF 抑制弓形虫 DNA 复制并增强 RNA 降解。
临床怎么用
- MCF 腹腔或口服给药在感染小鼠中提高存活率,口服在妊娠小鼠中预防垂直传播,支持其作为候选药物进一步开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Toxoplasmosis, a parasitic disease caused by Toxoplasma gondii, is an important cause of miscarriage or adverse fetal effects, including neurological and ocular manifestations in humans. Current anti-Toxoplasma drugs have limited efficacy against toxoplasmosis and also have severe side effects. Therefore, novel efficacious drugs are urgently needed. Here, we identified metacytofilin (MCF) from a fungal Metarhizium species as a potential anti-Toxoplasma compound. METHODS: Anti-Toxoplasma activities of MCF and its derivatives were evaluated in vitro and in vivo using nonpregnant and pregnant mice. To understand the mode of action of MCF, the RNA expression of host and parasite genes was investigated by RNAseq. RESULTS: In vitro, MCF inhibited the viability of intracellular and extracellular T. gondii. Administering MCF intraperitoneally or orally to mice after infection with T. gondii tachyzoites increased mouse survival compared with the untreated animals. Remarkably, oral administration of MCF to pregnant mice prevented vertical transmission of the parasite. Interestingly, RNA sequencing of T. gondii-infected cells treated with MCF showed that MCF inhibited DNA replication and enhanced RNA degradation in the parasites. CONCLUSIONS: With its potent anti-T. gondii activity, MCF is a strong candidate for future drug development against toxoplasmosis.
引用
- Leesombun A, Iijima M, Umeda K, et al. Metacytofilin Is a Potent Therapeutic Drug Candidate for Toxoplasmosis. J Infect Dis. 2020. PMID: 31573038. doi:10.1093/infdis/jiz501
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。